N Goldschlager, AE Epstein, G Naccarelli, B … - Archives of internal …, 2000 - ncbi.nlm.nih.gov Amiodarone has become an important drug for the treatment of supraventricular and ventricular
arrhythmias, in short-term inpatient and outpatient settings. It may also have a role in affecting
outcome in patients at high risk ... Cited by 113 - Related articles - BL Direct - All 5 versions
K Katariya, E DeMarchena, H Bolooki - The Annals of thoracic surgery, 1999 - Elsevier Methods. In this prospective study, 226 consecutive adult patients (group A) who had various heart
operations utilizing cardiopulmonary bypass between April and November of 1998 at the University of
Miami/Jackson Memorial Hospital, ... Cited by 36 - Related articles - BL Direct - All 4 versions
- ►bmj.com Y Kreiss, Y Sidi, H Gur - British Medical Journal, 1999 - pmj.bmj.com We examined the efficacy and safety of intravenous amiodarone in 20 unselected patients with
recent-onset atrial fibrillation who were admitted to a general internal medicine department during
a 6-month period. The treatment ... Cited by 29 - Related articles - BL Direct - All 6 versions
- ►physiology.org WH Chung, BM Bennett, WJ Racz, JF … - American Journal of …, 2001 - Am Physiological Soc Amiodarone (AM) is an antidysrhythmic agent with a propensity to cause pulmonary toxicity, including
potentially fatal fibrosis. In the present study, the potential roles of c-Jun and transforming
growth factor (TGF)- 1 in ... Cited by 15 - Related articles - BL Direct - All 3 versions
HF Tse, CP Lau - Clinical and Experimental Pharmacology and …, 1998 - interscience.wiley.com 2. The pathophysiology of AF is complex. Atrial fibrillation can be caused either by a single source
of very rapid impulses or, in the majority of cases, by multiple random re-entering wavelets. The
notion that AF may be initiated by ... Cited by 12 - Related articles - BL Direct - All 3 versions
MI Anastasiou-Nana, JN Nanas, G Alexopoulos, JN … - … Drugs and Therapy, 1999 - Springer Summary. Intravenous amiodarone has been found useful in the emergent management of life-threatening
arrhyth- mias. Experimental studies have shown that its electro- physiologic effects are
proportional to its myocardial con- ... Cited by 9 - Related articles - BL Direct - All 4 versions
MA Tijunelis, ME Herbert - … Canadian journal of emergency medical care …, 2005 - ncbi.nlm.nih.gov Wolff-Parkinson-White (WPW) syndrome with atrial fibrillation (AF) is a potentially life-threatening
problem requiring rapid conversion to sinus rhythm. The most recent American Heart Association
guidelines for the treatment of ... Cited by 8 - Related articles - BL Direct - All 5 versions
S Madonia, M De Simone, G Brai, D Gozzo, A … - Italian heart journal: …, 2000 - ncbi.nlm.nih.gov BACKGROUND: Non-valvular paroxysmal atrial fibrillation is a common clinical condition associated
with a high risk of thromboembolism and hemodynamic problems which increase with the duration of
arrhythmia. Therefore, even if ... Cited by 7 - Related articles - BL Direct - All 3 versions
G Durmus-Altun, A Altun, Y Sami Salihoglu, S … - International journal of …, 2004 - Elsevier Background: Amiodarone is a potent antiarrhythmic agent that is limited in clinical use by its
adverse effects, including potentially life threatening amiodarone-induced pulmonary toxicity
(AIPT). The alteration of ... Cited by 5 - Related articles - All 10 versions
WH Frishman, S Vahdat, S Bhatta - Journal of clinical pharmacology, 1998 - cat.inist.fr The survival rate of patients undergoing cardiopulmonary resuscitation(CPR) is 5% to 15%. New
treatment approaches under investigation for CPR include the use of vasopressin as a vasopressor,
amiodarone for the treatment of ... Cited by 10 - Related articles - BL Direct - All 7 versions
